Marker Therapeutics
MRKR
58 hedge funds and large institutions have $21.2M invested in Marker Therapeutics in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 18 reducing their positions, and 10 closing their positions.
0.02% less ownership
Funds ownership: 3.05% → 3.03% (-0.02%)
8% less funds holding
Funds holding: 63 → 58 (-5)
22% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 18
28% less capital invested
Capital invested by funds: $29.4M → $21.2M (-$8.2M)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$363K |
| 2 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$197K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$127K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$62.6K |
| 5 |
State Street
Boston,
Massachusetts
|
+$59.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$498K |
| 2 |
Renaissance Technologies
New York
|
-$169K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$139K |
| 4 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
-$118K |
| 5 |
RAM
Riggs Asset Management
Dallas,
Pennsylvania
|
-$77K |
MRKR Hedge Fund Activity: Q3 2020 in Review
58 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q3 2020, worth a combined $21.2M — down 28% from $29.4M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of MRKR and 5 opened new positions — a net loss of 5 holders — while 18 trimmed existing stakes and 14 added.
The largest buyer was Russell Investments Group, opening a new position worth an estimated $363K. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $498K sold.
- 58 institutional investors held Marker Therapeutics (MRKR) as of Q3 2020, down from 63 in Q2 2020.
- Funds reported $21.2M of Marker Therapeutics stock for Q3 2020, down 28% quarter-over-quarter.
- 5 funds opened new Marker Therapeutics positions in Q3 2020 and 10 closed out, a net change of -5 holders.
- The largest Marker Therapeutics buyer in Q3 2020 was Russell Investments Group, an estimated $363K added.
- The largest Marker Therapeutics seller in Q3 2020 was Baker Bros. Advisors, an estimated $498K sold.
Based on aggregated 13F filings for Q3 2020.